Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.
Patients' rights activists and health industry's big players are usually at odds with each other, but now they are championing similar tactics to tame prescription drug prices.
A Supreme Court Justice Brett Kavanaugh Could Be Disastrous for People Living With HIV, but He's Not The Worst Case Scenario
"While Kavanaugh's appointment to the Supreme Court might not spell the end of the Affordable Care Act it could certainly lead to the chipping away at protections for millions of Americans who benefit from it."
With Government Restructuring Plan, Trump Administration Takes Aim at Programs Used by People Living With HIV
The Trump administration is planning a radical reorganization of the federal government that could adversely impact people living with HIV.
The 2017 NHAS Progress Report was created in a political vacuum, almost entirely separated from the world in which HIV advocates live.
Despite the tremendous success of the program -- or perhaps because of it -- and courtesy of a substantial lobbying push from the Pharmaceutical Research and Manufacturers of America (PhRMA), the 340B program has found itself under close scrutiny by ...
A program that lowers drug costs for Ryan White clinics, community health centers, family planning clinics, and hospitals serving low-income patients is under attack by Republicans in Congress and the Trump Administration.
Big Pharma money can beef up public health efforts. But it can also distract from unchecked drug pricing -- and from government negligence.
Reining in prescription drug prices isn't so much a potential benefit of universal health care, but rather a factor in its affordability and success.
"The return on investment in this epidemic has been high," Allison Webel writes. "HIV is now a chronic, rather than fatal, disease throughout the world. New infections are dropping, and we are closer than we have ever been to achieving our goal of th...